Congressman Murphy (R-N.C.) Sends Letter to FDA Regarding Plans for AI Regulation
Summary
On January 3, 2024, Congressman Greg Murphy, M.D. sent a letter to the Food and Drug Administration (FDA) requesting responses to specific questions, including whether the agency supports a voluntary alternative pathway for review of AI products and/or a liability safe harbor for physician use of AI-enabled medical devices in the context of continued compliance with post-market surveillance programs.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.